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In conclusion, we do recommend that physicians screen 
TJA patients peri-operatively for Factor V Leiden 
mutation, G20210A prothrombin mutation, and PAI-1 
4G/4G genotype. Detecting these genetic polymorphisms 
could be a good step to prevent the incidence of 
postoperative venous thromboembolism following TJA. 
However, the, ACE deletion/ deletion genotype are 
similarly unlikely to be associated with VTE. Moreover, 
patients that develop DVT might benefit from 
perioperative screening for PAI-1 4G/4G to determine if 
they are likely to be resistant to anticoagulation therapy. 
Patients would benefit from a screen for MTHFR 
polymorphisms; however, orthopedic surgeons should be 
aware that only compound heterozygotes for the C677T or 
A1298C polymorphisms have shown to be resistant to
anticoagulation. Moreover, patients may also benefit from 
screening for SNP rs710446 of the KNG1 gene and SNP 
rs20069588 for the BDK482 gene, as well as the Factor 
XI C25265C polymorphism. These patients would benefit 
from more aggressive anticoagulation protocols.
Abstract Results
This systematic review and meta-analysis were conducted 
according to the preferred
reporting items for systematic review and meta-analysis 
(PRISMA) guidelines (11) and the Cochrane Handbook.(12)
Introduction
The estimated rates of total hip arthroplasties (THA) and total knee 
arthroplasties (TKA) are projected to increase in the United States. Data 
obtained from the U.S. Census Bureau and US National Inpatient Sample 
projects the rate of THA to increase by 34%, 75%, 129%, and 284% by 
the years 2020, 2025, 2030, and 2040, respectively(1). Moreover, the rate 
of TKA is projected to increase by 56%, 110%, 182%, and 401%, 
respectively(1). Data from the National Input Sample determines that 
1.3% of the patients who received THA or TKA between 2009 and 2011 
develop a hospital acquired condition (HAC)(2). Thromboembolic 
events, including pulmonary embolism (PE) and deep vein thrombosis 
(DVT) are common, life-threatening but preventable HCAs that occur 
following TJA(3). Thromboembolism has multifactorial etiology and so 
contributing risk factors are environmental and genetic. Some 
environmental risk factors are provoking e.g. cancer, surgery, trauma, 
immobilization, pregnancy, long distance travel, hospitalization, 
catheterization, and acute infection(4). Other environmental risk factors 
are intrinsic to the patient e.g. age, sex, ethnicity, body mass index, oral 
contraceptive use, corticosteroid use, statin use, diet, physical activity, 
and air pollution(4). There are many risk factors that specifically 
contribute to VTE following TJA. A metanalysis of 14 case-control or 
prospective cohort studies found a significant relationship between VTE 
following TJA and prior history of VTE (RR > 10.6), varicose vein (RR > 
2.7), and congestive cardiac failure (RR = 2) (5). There was a VTE risk 
ranging from 8-30% for other factors which are listed in order of 
increasing risk: female gender, age > 80, hypertension, active cancer, 
BMI > 30, black race(5). Many genetic risk factors have also been 
identified, including factor V Leiden mutation and prothrombin gene 
polymorphisms(4). Moreover, Wang et al. applied genetic risk scoring to 
known genetic polymorphisms associated with hemostatic disease 
provided 70.8% precision in identifying patients with VTE(6), which 
further supports a genetic role in VTE development.
Data Collection & Analysis
A total of 23 publications were identified from the 
literature search specific to Hospital-Acquired 
Venous Thromboembolism or Bleeding Following 
Total Joint Arthroplasty. 
Meta-analysis:
1. Factor V Leiden (FVL) G1691A polymorphism Seventeen clinical trials 
(15-30) investigated the association of FVL (G1691A polymorphism) in 
Caucasian (14 trials) and Asian (3 trials) populations with VTE following 
TJA. The pooled results showed that FVL- G1691A polymorphism, in 
Caucasian populations, is statistically significant associated with the 
incidence of VTE following TJA. [OR= 1.39(95% CI, 1.03-1.88; p value = 
0.03) [figure.3.] Asian population showed no association between FVL 
polymorphism and the incidence of VTE. 
2. Angiotensin Converting Enzyme (ACE) deletion/ deletion (D/D) 
genotype Three trials (18, 19) investigated the association of Angiotensin 
Converting Enzyme (ACE) (D/D) genotype in Caucasian populations with 
VTE following TJA. The pooled results showed that there is no statistically 
significant association between ACE-D/D polymorphism-regardless, the 
population- and the incidence of VTE. [OR= 1.40 (95% CI, 0.90-2.19; p 
value = 0.13] [figure.3.]
3. Prothrombin gene (G20210A) Twelve clinical trials(16, 17, 20-24, 27-29, 
31, 32) investigated the association of PG (G20210A polymorphism) in 
Caucasian (7 trials) and Asian (5 trials) populations with VTE following 
TJA. The pooled results showed that PG-G20210A polymorphism, in 
Caucasian populations, is statistically significant associated with the 
incidence of VTE following TJA. [OR= 2.24 (95% CI, 1.37-3.66; p value = 
0.001] [figure.4.] Asian population showed no association between FVL 
polymorphism and the incidence of VTE.
4. Methylenetetrahydrofolate Reductase (C677T/TT) genotype Eight 
trials (16, 20-22, 24, 29, 32, 33) investigated the association of 
Methylenetetrahydrofolate Reductase (C677T/TT) in Caucasian (5 trials) and 
Asian (3 trials) with VTE following TJA . The pooled results showed that 
there is no statistically significant association between MTFR 
polymorphism-regardless the population- and the incidence of VTE. [OR= 
0.97 (95% CI, 0.69-1.38; p value = 0.88] [ figure.4.]
5. Plasminogen activator inhibitor-1 (PAI-1) 4G/4G genotype Four trials 
(16, 24, 29, 34) investigated the association of PAI-1 4G/4G polymorphism 
in Caucasian populations with VTE following TJA. The pooled results 
showed that PAI-1 4G/4G polymorphism, in Caucasian populations, is 
statistically significant associated with the incidence of VTE following TJA. 
[OR= 1.72 (95% CI, 1.01-2.93; p value = 0.05) [figure.4.]
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Figure 1: Strengthening the Reporting of 
Genetic Association Studies (STREGA)
Table 1: Literature Search
Using the previously mentioned keywords, 304 relevant articles 
were obtained from the 3 online databases (PubMed, MEDLINE 
via Ovid, and Web of Science) as well as through manual 
retrieving. After screening and assessing eligibility, 23 clinical 
studies that investigated the association of genetic 
polymorphism and the incidence of venous thromboembolism 
following hip and knee arthroplasties were included. Only one 
of these 23 studies were randomized controlled trial. However, 
the remaining studies were prospective cohort (5 trials), 
retrospective cohort (2 trials) and case-control trials (15 trials). 
A flow chart demonstrating the study selection,
inclusion, and exclusion process is shown in (Figure 1). Study 
Characteristics. One Randomized Controlled triol (RCT), two 
retrospective cohort, five prospective cohort, and 17 case-
control studies of the study period between 1997 and 2018 have 
examined the genetic association with the incidence of VTE. 
8098 patients were enrolled in the 23 studies. A total of 69.5% 
(16/23) trials have studies these association in Caucasian 
population. However, Asian population were the subjects in 7 
trials. The mean age of the VTE group across all studies was 
66.3, while that in the non-VTE group was 65.1. A total of 
36.3% (8/23) trials have been conducted in the United States, 
three trials in China, two trials in Italy (2/23) and Korea (2/23) 
While the other six trials came from Japan (1/23), Sweden 
(1/23), Hungary(1/23), Germany (1/23), India (1/23), and 
Australia (1/23).
The studies included in this meta-analysis contained an average STREGA score of 7.9 with a median 
of 7, mode of 7, and range of 7-11. Many of the studies stated the objectives and hypothesis, 
provided clear eligibility criteria, defined all variables, contained replicable statistical methods, 
provided sufficient descriptive data (e.g. age, gender), and stated genotype frequencies. However, 
many of the studies omitted an assessment of Hardy Weinberg equilibrium and ethnicity. The 
descriptive statistics for each criterion of the STREGA methodology score are described in table 
(Table 2). The methodological quality the total STREGA methodology score was plotted against 
year of publication to estimate the trend of methodological quality (Figure 3). There is a negative 
correlation (r2 = 0.06969, slope- - 0.05852).
